From the analyst's couch: TLR-targeted therapeutics.
Hoffman
Eric S
ES
J.P. Morgan, 50 Rowes Wharf, Boston, Massachusetts 02110, USA. eric.s.hoffman@jpmorgan.com
Smith
Richard E T
RE
Renaud
Ronald C
RC
D000276:Adjuvants, Immunologic / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D000634:Aminoquinolines / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D007113:Immunity, Innate / Q000187:drug effects* / Q000276:immunology; D040541:Marketing; D051193:Toll-Like Receptors / Q000276:immunology / Q000378:metabolism*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D051193:Toll-Like Receptors; D000077271:Imiquimod